Interim report 1 January – 30 June 2024

Good growth in both Business Areas and continued profitability improvement


  
The companies within AddLife showed strong performance development during the quarter. In Labtech, sales growth recovered as expected and margins remained stable. Sales growth in Medtech was good and margins improved partly driven by restructuring efforts that are now yielding clear results. Cash flow improved significantly and after the end of the quarter, an acquisition was made in line with our updated long-term strategy. 
   

Fredrik Dalborg, President and CEO 

1 APRIL – 30 JUNE 2024 (3 MONTHS)

  • Net sales increased by 8% to SEK 2,554m (2,365). The organic growth, excluding exchange rate changes, was 7%. 
  • EBITA increased by 21% to SEK 299m (247), corresponding to an EBITA-margin of 11.7% (10.4). 
  • Profit after tax for the quarter increased by 116% to SEK 72m (33).
  • Earnings per share amounted to SEK 0.60 (0.27).
  • Cash flow from operating activities amounted to SEK 195m (82).

 

1 JANUARY – 30 JUNE 2024 (6 MONTHS)

  • Net sales increased by 6% to SEK 5,124m (4,822). The organic growth, excluding exchange rate changes, was 5%. 
  • EBITA decreased by 4% to SEK 590m (613), corresponding to an EBITA-margin of 11.5% (12.7). EBITA includes reversed contingent considerations of SEK 7m (83). Adjusted for this EBITA increased by 10% and the EBITA margin amounted to 11.4% (11.0).
  • Profit after tax for the period amounted to SEK 135m (207).
  • Earnings per share amounted to SEK 1.11 (1.70). Earnings per share for the last 12 months amounted to SEK 0.97 (3.19)
  • Cash flow from operating activities amounted to SEK 292m (187).
  • The equity ratio was 39% (39).
  • Return on working capital (P/WC) amounted to 48% (50).
  3 months ending 6 months ending 12 months ending
SEKm 30 Jun 24 30 Jun 23 change 30 Jun 24 30 Jun 23 change 30 Jun 24 31 Dec 23
Net sales 2,554 2,365 8% 5,124 4,822 6% 9,987 9,685
EBITA 299 247 21% 590 613 -4% 1,112 1,135
EBITA-margin 11.7% 10.4%   11.5% 12.7%   11.1% 11.7%
Profit before tax 113 70 62% 213 276 -23% 276 339
Profit for the period 72 33 116% 135 207 -35% 120 192
Earnings per share before dilution, SEK 0.60 0.27 122% 1.11 1.70 -35% 0.97 1.56
Earnings per share after dilution, SEK 0.60 0.27 122% 1.11 1.70 -35% 0.97 1.56
Dynamisk graf: Net sales (SEKm)
Dynamisk graf: EBITA (SEKm)
  3 months ending 6 months ending
One-off costs, SEKm 30 Jun 24 30 Jun 23 30 Jun 24 30 Jun 23
Restructuring reserve Camanio Health – – -6 –
Reversed contingent consideration 7 – 7 83
Total one-off costs 7 – 1 83
         
  3 months ending 6 months ending
Classification in income statement, SEKm 30 Jun 24 30 Jun 23 30 Jun 24 30 Jun 23
Cost of sales – – – –
Selling expenses – – -1 –
Administrative expenses – – -2 –
Research and Development – – -3 –
Other operating income and expenses 7 – 7 83
Total one-off costs in the income statement 7 – 1 83
Latest updated: 7/14/2024 7:46:52 PM by lina.astrom@add.life
NEXT